Sparfloxacin Procainamide

Clinically important, potentially hazardous interactions with amiodarone, bepridil, cisapride, disopyramide, droperidol, erythromycin, flecainide, levodopa, pentamidine, procainamide, quinidine, sotalol, sparfloxacin, terfenadine, thioridazine... 

Clinically important, potentially hazardous interactions with abacavir, amiodarone, bretylium, chlorpromazine, ciprofloxacin, disopyramide, enoxacin, fluphenazine, gatifloxacin, lomefloxacin, mesoridazine, moxifloxacin, norfloxacin, ofloxacin, phenothiazines, procainamide, prochlorperazine, promethazine, quinidine, quinolones, sotalol, sparfloxacin, thioridazine, trifluoperazine... 

Leukopenia, eosinophilia, and mild elevations in serum transaminases occur rarely. Prolongation of the QT interval has been observed with sparfloxacin and to a lesser extent with gati-floxacin and moxifloxacin. Quinolones probably should be used only with caution in patients who are taking certain antiarrhythmics, including amiodarone, quinidine, and procainamide (see Chapter 34). 

Ofloxacin and levofloxacin cause moderate increases in the serum levels of procainamide, whereas ciprofloxacin has a lesser effect However, the ECG appears to be unaltered in studies in healthy subjects given these quinolones with procainamide. An increased risk of torsade de pointes would be expected if procainamide is used with gatifloxacin, moxifloxacin, or sparfloxacin, and possibly levofloxacin. 

Of the quinolones used clinically, gatifloxacin, moxifloxacin, and sparfloxacin are known to prolong the QT interval (see Table 9.2 , (p.257)) and would be expected to increase the risk of torsade de pointes arrhythmias when used with procainamide. These quinolones should probably be avoided in patients on procainamide (see also Drugs that prolong the QT interval + Other drugs that prolong the QT interval , p.257). 

---